Advanced search
Publication Cover
Cancer Biology & Therapy Volume 14, 2013 - Issue 6
Submit an article Journal homepage
2,589
Views
32
CrossRef citations to date
0
Altmetric
Research Paper

Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

Aisling Pierce Education and Research Centre; St. Vincent’s University Hospital; Dublin, Ireland; UCD School of Medicine and Medical Science; Conway Institute of Biomolecular and Biomedical Research; University College Dublin; Dublin, Ireland
,
Patricia M. McGowan Education and Research Centre; St. Vincent’s University Hospital; Dublin, Ireland; UCD School of Medicine and Medical Science; Conway Institute of Biomolecular and Biomedical Research; University College Dublin; Dublin, IrelandCorrespondence[email protected]
,
Maura Cotter Education and Research Centre; St. Vincent’s University Hospital; Dublin, Ireland; UCD School of Medicine and Medical Science; Conway Institute of Biomolecular and Biomedical Research; University College Dublin; Dublin, Ireland
,
Maeve Mullooly Education and Research Centre; St. Vincent’s University Hospital; Dublin, Ireland; UCD School of Medicine and Medical Science; Conway Institute of Biomolecular and Biomedical Research; University College Dublin; Dublin, Ireland
,
Norma O’Donovan National Institute for Cellular Biotechnology; Dublin City University; Dublin, Ireland
,
Sweta Rani School of Pharmacy and Pharmaceutical Sciences; Panoz Institute; Trinity College; Dublin, Ireland
,
Lorraine O’Driscoll School of Pharmacy and Pharmaceutical Sciences; Panoz Institute; Trinity College; Dublin, Ireland
,
John Crown Department of Medical Oncology; St Vincent’s University Hospital; Dublin, Ireland
&
Michael J. Duffy UCD School of Medicine and Medical Science; Conway Institute of Biomolecular and Biomedical Research; University College Dublin; Dublin, Ireland; UCD Clinical Research Centre; St Vincent’s University Hospital; Dublin, Ireland
 show all
Pages 537-545 | Received 07 Jan 2013, Accepted 18 Mar 2013, Published online: 10 Apr 2013

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
Source: Elsevier BV
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).
Source: American Society of Clinical Oncology (ASCO)
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Source: Springer Science and Business Media LLC
Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Source: Wiley
FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells
Source: Cold Spring Harbor Laboratory
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
Source: Elsevier BV
FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1‐defective cells
Source: EMBO
Poly(ADP‐Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
Source: Wiley
Hallmarks of 'BRCAness' in sporadic cancers
Source: Springer Science and Business Media LLC
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Source: Elsevier BV
Drug resistance caused by reversion mutation.
Source: American Association for Cancer Research (AACR)
PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
Source: The University of North Carolina at Chapel Hill University Libraries
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Source: Elsevier BV
Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
Source: American Association for Cancer Research (AACR)
Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity
Source: Springer Science and Business Media LLC
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Source: American Association for Cancer Research (AACR)
VARYINGEFFICIENCYOFPHARMACOLOGICALPARPINHIBITORS
Source: Wiley
PARP inhibition: PARP1 and beyond
Source: Springer Science and Business Media LLC
Making the best of PARP inhibitors in ovarian cancer
Source: Springer Science and Business Media LLC

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.